An observational study in Amyloid Cardiomyopathy and Block, AV, sponsored by Steen Hvitfeldt Poulsen. Recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Steen Hvitfeldt Poulsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark — 6 open to participants now, 7 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Denmark.
Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, this one is the only one that started in 2022, is one of 2 observational ones, and was the 5th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →6 of the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Denmark, United States, Argentina and 21 more countries
Ages 18–75
Steen Hvitfeldt Poulsen · Sites in Denmark
Ages 65+
Rigshospitalet, Denmark · Sites in Denmark
Ages 65+ · Men only
Alnylam Pharmaceuticals · Sites in Denmark, United States, Brazil and 9 more countries
Region Skane · Sites in Denmark, Sweden
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 170 is below the median of 233 across 92 observational studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 200 across the 9 interventional studies, 835 across the 2 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 6 most frequent:
Steen Hvitfeldt Poulsen is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Steen Hvitfeldt Poulsen has 4 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyloid Neuropathies, Familial with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07435168Rigshospitalet, DenmarkCHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.
Patients admitted for pacemakerimplantation with advanced AV-block fulfilling eligibility criteria as described.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.
Diagnostic Test: Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)
Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent. DPD-scintigraphy. (Echocardiography)
Diagnosis of ATTRwt in study cohort.
Number of participants with a diagnosis of ATTRwt in the study cohort based on DPD-scintigraphy or if necessary, a cardiac biopsy.
Time frame: 3 years
Characteristics of patients with ATTRwt
Echocardiographic (Left ventricular (LV) wall thickness, LV cavity dimension, EF, GLS, diastolic function, Right Ventricular (RV) systolic function, valve disease) Biochemical profile (Troponin I, NT-pro-BNP, Renal Function (E-GFR) ), presence or history of spinal stenosis, carpal tunnel syndrome
Time frame: 3 years
Clinical Stage of time of diagnosis in patients with ATTRwt
Gilmore Staging
Time frame: 3 years
Number of heart-failure associated hospitalization among ATTRwt patients
Time frame: 5 years
All-cause mortality among ATTRwt patients.
Time frame: 5 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Aug 2025, 34 months after the start.
Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 34 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →
Steen Hvitfeldt Poulsen